产品名称：Daratumumab
中文名称：达妥木单抗, 达雷木单抗
产品别称：HuMax-CD38
靶点：CD38[Homo sapiens]
抗体亚型：IgG1 - kappa
体内研究：在小鼠异体移植肿瘤模型中，daratumumab具有高活性并阻断异种移植物肿瘤生长[1]。
| Animal Model | 8- to 10-wk-old C.B-17 SCID mice (luciferase-expressing Daudi cells) |
| Dosage | 0.5 mg/kg |
| Result | Effectively inhibited tumor growth compared with control-treated animals in which tumor grew rapidly and therefore required euthanasia on day 35. On day 28 and day 35, tumor size in Daratumumab-treated animals was significantly different from the control. |
体外研究：Daratumumab在表达cd38的淋巴瘤和MM来源细胞系以及患者MM细胞中诱导了有效的ab依赖性细胞毒性，包括自体和异体效应细胞[1]。
参考文献：1. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-1848. doi:10.4049/jimmunol.1003032
仅供科研使用
